News
-
09.02.2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C - -
04.02.2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
Home
PRESS RELEASES
| Debio 0928 |
|
Debio 0928 is a small molecule inhibitor of Raf1-Rb interactions. Raf1 is a key signalling kinase in the MAP kinase pathway, which is frequently activated in tumours due to mutations of signalling proteins or absence of negative regulatory feedback mechanisms. Inhibitors of Raf1-Rb interactions have shown efficacy in mice in various tumour xenografts.
Press Releases18-Jun-2009
|



